Please enable JavaScript to continue using this application.

Compare $ACHV vs $GYRE | Chartloom

Compare

$ACHV vs $GYRE

Achieve Life Sciences Inc · Gyre Therapeutics Inc

ACHV

Achieve Life Sciences Inc

GYRE

Gyre Therapeutics Inc

Compare $ACHV vs $GYRE

Comparing Achieve Life Sciences Inc and Gyre Therapeutics Inc

ACHVAchieve Life Sciences Inc

GYREGyre Therapeutics Inc

ACHVAchieve Life Sciences Inc

Market cap

$761M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-89.3%

YTD performance

49.1%

52W performance

114.8%

FCF yield

-6.2%

GYREGyre Therapeutics Inc

Market cap

$643M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

16.8%

YTD performance

3.4%

52W performance

-3.6%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACHV

GYRE

Detailed metrics comparison

ACHV

Achieve Life Sciences Inc

GYRE

Gyre Therapeutics Inc

Market Cap

ACHV$761M

GYRE$643M

Enterprise Value

ACHV$728M

GYRE$600M

Price

ACHV$7.41

GYRE$7.04

P/E Ratio

ACHVN/A

GYREN/A

P/S Ratio

ACHV41.81x

GYRE5.39x

EV/Sales

ACHV39.95x

GYRE5.03x

EV/EBITDA

ACHV0.00x

GYRE286.88x

P/B Ratio

ACHV69.77x

GYRE5.78x

P/FCF Ratio

ACHVN/A

GYREN/A

EV/FCF

ACHV-15.41x

GYRE-35.74x

PEG Ratio

ACHVN/A

GYREN/A

Forward P/E (NTM)

ACHVN/A

GYREN/A

Forward P/S (NTM)

ACHVN/A

GYREN/A

Revenue (TTM)

ACHV$0

GYRE$119M

Revenue Growth (YoY)

ACHV-89.3%

GYRE16.8%

Forward Rev Growth

ACHV281.2%

GYRE21.1%

Gross Margin (TTM)

ACHV0.0%

GYRE94.3%

Operating Margin (TTM)

ACHV0.0%

GYRE0.0%

EBITDA Margin (TTM)

ACHV0.0%

GYRE-8.5%

Net Margin (TTM)

ACHV0.0%

GYRE-15.5%

FCF Margin (TTM)

ACHVN/A

GYRE-14.1%

Net Income (TTM)

ACHV$-114M

GYRE$-18M

FCF (TTM)

ACHV$-47M

GYRE$-17M

EPS (TTM)

ACHV-$1.22

GYRE-$0.18

ROE (TTM)

ACHV-19349.0%

GYRE-1584.0%

ROA (TTM)

ACHV-14373.0%

GYRE-1014.0%

ROIC (TTM)

ACHV-13245.0%

GYRE-1584.0%

Cash

ACHV$48M

GYRE$43M

Debt

ACHV$15M

GYRE$0

Net Cash/Debt

ACHV$33M

GYRE$43M

Current Ratio (TTM)

ACHV0.95x

GYRE4.26x

Quick Ratio (TTM)

ACHV0.95x

GYRE3.64x

Debt/Equity (TTM)

ACHV1.40x

GYRE0.00x

Debt/Assets (TTM)

ACHV0.0%

GYRE0.0%

Interest Coverage (TTM)

ACHVN/A

GYREN/A

Net Debt/EBITDA (TTM)

ACHV0.00x

GYRE0.00x

Beta

ACHV2.44

GYRE2.46

52W Performance

ACHV114.8%

GYRE-3.6%

YTD Performance

ACHV49.1%

GYRE3.4%

% from 52W High

ACHV-14.2%

GYRE-25.3%

% from 52W Low

ACHV182.8%

GYRE29.4%

Asset Turnover (TTM)

ACHV0.33x

GYRE0.70x

FCF Yield (TTM)

ACHV-6.2%

GYRE-2.6%

Earnings Yield (TTM)

ACHV-15.0%

GYRE-2.9%

Dividend Yield (TTM)

ACHVN/A

GYREN/A

Rule of 40

ACHV-89.3

GYRE2.8

EV/GP/RG

ACHVN/A

GYRE0.23

Ticker research

View ACHV research View GYRE research

Metric	ACHV Achieve Life Sciences Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$761M	$643M
Enterprise Value	$728M	$600M
Price	$7.41	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	41.81x	5.39x
EV/Sales	39.95x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	69.77x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.41x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$119M
Revenue Growth (YoY)	-89.3%	16.8%
Forward Rev Growth	281.2%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-8.5%
Net Margin (TTM)	0.0%	-15.5%
FCF Margin (TTM)	N/A	-14.1%
Net Income (TTM)	$-114M	$-18M
FCF (TTM)	$-47M	$-17M
EPS (TTM)	-$1.22	-$0.18
ROE (TTM)	-19349.0%	-1584.0%
ROA (TTM)	-14373.0%	-1014.0%
ROIC (TTM)	-13245.0%	-1584.0%
Financial Health
Cash	$48M	$43M
Debt	$15M	$0
Net Cash/Debt	$33M	$43M
Current Ratio (TTM)	0.95x	4.26x
Quick Ratio (TTM)	0.95x	3.64x
Debt/Equity (TTM)	1.40x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.44	2.46
52W Performance	114.8%	-3.6%
YTD Performance	49.1%	3.4%
% from 52W High	-14.2%	-25.3%
% from 52W Low	182.8%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.33x	0.70x
FCF Yield (TTM)	-6.2%	-2.6%
Earnings Yield (TTM)	-15.0%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-89.3	2.8
EV/GP/RG	N/A	0.23
Ticker research	View ACHV research	View GYRE research

Valuation

P/S Ratio

GYRE

5.39x

ACHV

41.81x

EV/FCF

GYRE

-35.74x

ACHV

-15.41x

Growth & revenue

Revenue Growth TTM

GYRE

16.8%

ACHV

-89.3%

Forward Revenue Growth

ACHV

281.2%

GYRE

21.1%

Profitability & performance

Gross Margin

GYRE

94.3%

ACHV

0.0%

ROE

GYRE

-1584.0%

ACHV

-19349.0%

FCF Yield %

GYRE

-2.6%

ACHV

-6.2%

52-Week Performance

ACHV

114.8%

GYRE

-3.6%

Detailed metrics comparison

ACHV

Achieve Life Sciences Inc

GYRE

Gyre Therapeutics Inc

Market Cap

ACHV$761M

GYRE$643M

Enterprise Value

ACHV$728M

GYRE$600M

Price

ACHV$7.41

GYRE$7.04

P/E Ratio

ACHVN/A

GYREN/A

P/S Ratio

ACHV41.81x

GYRE5.39x

EV/Sales

ACHV39.95x

GYRE5.03x

EV/EBITDA

ACHV0.00x

GYRE286.88x

P/B Ratio

ACHV69.77x

GYRE5.78x

P/FCF Ratio

ACHVN/A

GYREN/A

EV/FCF

ACHV-15.41x

GYRE-35.74x

PEG Ratio

ACHVN/A

GYREN/A

Forward P/E (NTM)

ACHVN/A

GYREN/A

Forward P/S (NTM)

ACHVN/A

GYREN/A

Revenue (TTM)

ACHV$0

GYRE$119M

Revenue Growth (YoY)

ACHV-89.3%

GYRE16.8%

Forward Rev Growth

ACHV281.2%

GYRE21.1%

Gross Margin (TTM)

ACHV0.0%

GYRE94.3%

Operating Margin (TTM)

ACHV0.0%

GYRE0.0%

EBITDA Margin (TTM)

ACHV0.0%

GYRE-8.5%

Net Margin (TTM)

ACHV0.0%

GYRE-15.5%

FCF Margin (TTM)

ACHVN/A

GYRE-14.1%

Net Income (TTM)

ACHV$-114M

GYRE$-18M

FCF (TTM)

ACHV$-47M

GYRE$-17M

EPS (TTM)

ACHV-$1.22

GYRE-$0.18

ROE (TTM)

ACHV-19349.0%

GYRE-1584.0%

ROA (TTM)

ACHV-14373.0%

GYRE-1014.0%

ROIC (TTM)

ACHV-13245.0%

GYRE-1584.0%

Cash

ACHV$48M

GYRE$43M

Debt

ACHV$15M

GYRE$0

Net Cash/Debt

ACHV$33M

GYRE$43M

Current Ratio (TTM)

ACHV0.95x

GYRE4.26x

Quick Ratio (TTM)

ACHV0.95x

GYRE3.64x

Debt/Equity (TTM)

ACHV1.40x

GYRE0.00x

Debt/Assets (TTM)

ACHV0.0%

GYRE0.0%

Interest Coverage (TTM)

ACHVN/A

GYREN/A

Net Debt/EBITDA (TTM)

ACHV0.00x

GYRE0.00x

Beta

ACHV2.44

GYRE2.46

52W Performance

ACHV114.8%

GYRE-3.6%

YTD Performance

ACHV49.1%

GYRE3.4%

% from 52W High

ACHV-14.2%

GYRE-25.3%

% from 52W Low

ACHV182.8%

GYRE29.4%

Asset Turnover (TTM)

ACHV0.33x

GYRE0.70x

FCF Yield (TTM)

ACHV-6.2%

GYRE-2.6%

Earnings Yield (TTM)

ACHV-15.0%

GYRE-2.9%

Dividend Yield (TTM)

ACHVN/A

GYREN/A

Rule of 40

ACHV-89.3

GYRE2.8

EV/GP/RG

ACHVN/A

GYRE0.23

Ticker research

View ACHV research View GYRE research

Metric	ACHV Achieve Life Sciences Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$761M	$643M
Enterprise Value	$728M	$600M
Price	$7.41	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	41.81x	5.39x
EV/Sales	39.95x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	69.77x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.41x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$119M
Revenue Growth (YoY)	-89.3%	16.8%
Forward Rev Growth	281.2%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-8.5%
Net Margin (TTM)	0.0%	-15.5%
FCF Margin (TTM)	N/A	-14.1%
Net Income (TTM)	$-114M	$-18M
FCF (TTM)	$-47M	$-17M
EPS (TTM)	-$1.22	-$0.18
ROE (TTM)	-19349.0%	-1584.0%
ROA (TTM)	-14373.0%	-1014.0%
ROIC (TTM)	-13245.0%	-1584.0%
Financial Health
Cash	$48M	$43M
Debt	$15M	$0
Net Cash/Debt	$33M	$43M
Current Ratio (TTM)	0.95x	4.26x
Quick Ratio (TTM)	0.95x	3.64x
Debt/Equity (TTM)	1.40x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.44	2.46
52W Performance	114.8%	-3.6%
YTD Performance	49.1%	3.4%
% from 52W High	-14.2%	-25.3%
% from 52W Low	182.8%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.33x	0.70x
FCF Yield (TTM)	-6.2%	-2.6%
Earnings Yield (TTM)	-15.0%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-89.3	2.8
EV/GP/RG	N/A	0.23
Ticker research	View ACHV research	View GYRE research